RE: From the RNS14 Dec 2022 17:59
It’s important to try see where they could get this over next 6 months as it’s this period where things become urgent.
As Said they had £389,000 or so in Sept accounts.
If you look through the year and add the costings you can see what the trials cost and overheads.
I have no doubt that they will be running as lean as possible to conserve income till they hopefully get someone to invest in the business.
NXP002 will be the inflection point after data I would expect they could begin possible interest with parties who may or may not be informed or interested. I’m sure there are parties but how interested at this early stage as there is another stage to do to get ready for Phase1.
I would say majority of the spare cash has gone to fund this latest trials with Lanstead cash covering current ongoings. So lights are on for now subject to deal!!
Very binary. Good data first needed!!! (We need to wait and see) we thought dilution was easy and look what happened!
Then a party willing to bail the company out with a deal. It’s definitely not a good situation to be in. Every time we have needed further funding with more goal posts it doesn’t matter who was at the top all them have slipped up on that fact. China, Japan, Lanstead!!! All these options have not materialised as hoped for one reason or another! That’s true and this position is the most dangerous yet for sure.